Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,099
  • Shares Outstanding, K 16,130
  • Annual Sales, $ 9,540 K
  • Annual Income, $ -151,180 K
  • 60-Month Beta 3.42
  • Price/Sales 4.28
  • Price/Cash Flow 1.29
  • Price/Book 0.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.93
  • Number of Estimates 1
  • High Estimate -0.93
  • Low Estimate -0.93
  • Prior Year -0.95
  • Growth Rate Est. (year over year) +2.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 +10.48%
on 11/19/19
2.64 -12.12%
on 12/05/19
-0.06 (-2.52%)
since 11/08/19
3-Month
2.05 +13.17%
on 10/02/19
3.09 -24.92%
on 11/05/19
+0.09 (+4.04%)
since 09/10/19
52-Week
2.01 +15.42%
on 08/06/19
11.63 -80.04%
on 02/04/19
-1.82 (-43.96%)
since 12/10/18

Most Recent Stories

More News
Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the KIT...

CLDX : 2.32 (+0.87%)
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.

MRK : 89.10 (+0.43%)
BMY : 62.09 (+1.32%)
LLY : 120.65 (+0.34%)
CLDX : 2.32 (+0.87%)
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 10.71% and -56.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CLDX : 2.32 (+0.87%)
Celldex: 3Q Earnings Snapshot

HAMPTON, N.J. (AP) _ Celldex Therapeutics Inc. (CLDX) on Tuesday reported a loss of $11.4 million in its third quarter.

CLDX : 2.32 (+0.87%)
Celldex Provides Corporate Update and Reports Third Quarter 2019 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019.

CLDX : 2.32 (+0.87%)
Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

-CDX-0159 IND accepted; Phase 1 study to start by YE 2019-

CLDX : 2.32 (+0.87%)
CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study-

CLDX : 2.32 (+0.87%)
Celldex Therapeutics Announces Upcoming Data Presentations

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences.

CLDX : 2.32 (+0.87%)
Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder, Executive Vice President and Chief Scientific...

CLDX : 2.32 (+0.87%)
Why Is Celldex (CLDX) Down 2.3% Since Last Earnings Report?

Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CLDX : 2.32 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade CLDX with:

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

2nd Resistance Point 2.39
1st Resistance Point 2.36
Last Price 2.32
1st Support Level 2.28
2nd Support Level 2.23

See More

52-Week High 11.63
Fibonacci 61.8% 7.95
Fibonacci 50% 6.82
Fibonacci 38.2% 5.68
Last Price 2.32
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar